NEW ISSUE OF GOLD
Download the latest issue of GOLD now! From reviewing the pharmaceutical industry’s return to prosperity, to finding a silver lining for patient centricity, the November issue reflects on the effect COVID-19 has had on the pharma industry, and how its future growth and direction will be influenced by this
Catalyst of Pharma
Mary Pinder-Schenk, Vice President and Head, Global Oncology Medical Affairs, Daiichi Sankyo speaks to us about the privilege of helping patients and her plans for shaping Daiichi Sankyo’s future.
Business strategies over the past 18 months focussed on providing stability, but as the dust begins to settle from the pandemic, the pharmaceutical industry is moving from continuity back to growth.
The Hard Sell of Cell
and Gene Therapies
The high cost of cell and gene therapies (CGTs) raises concerns from payers. We explore how the industry can drive adoption to ensure that CGTs reach the many, rather than the few.
A Discussion on the Pandemic and Gender Parity
In our roundtable, two industry thought leaders discuss how the pharmaceutical industry is harnessing the pandemic to advance rather than derail their mission to improve female representation across the sector.
The value of real-world data during the pandemic was unprecedented, and now the pharmaceutical industry must harness its learnings to shape into its future approach to RWD.
Take a look at pharmaceutical trade trends around the world…
WE TALK TO...
International CEO, WPP Health Practice
We sit down with Claire Gillis, who discusses how the communications role can transform patient outcomes.
Global Head Biopharmaceuticals, Sandoz
Pierre Bourdage provides insight into the state and future of the biosimilars market and discusses how to adapt to ‘the new normal'.
Vice President Hematology EMEA, Commercial Strategy Lead, Janssen
Mircea Cubillos discusses progression in oncology during COVID-19, and cultivating healthy habits during lockdown.